Subject: Fwd: Activity 2.1.1 - follow-up
From: Keti Khizanishvili <[email-masked]>
To: turkia babilina <[email-masked]>, ketevan shermadini <[email-masked]>, Anzor tchavtchavadze <[email-masked]>, Ekaterine Adamia <[email-masked]>, [email-masked], [email-masked], [email-masked]
Cc: Vladimer Getia <[email-masked]>, [email-masked], [email-masked], Lela Kvachantiradze <[email-masked]>
Date: Mon, 13 Jul 2020 18:28:25 +0000

ძვირფასო კოლეგებო,

დღეს, 13 ივლისს NCA-ს ჩამოყალიბების შესახებ ტელეკონფერენციის დასრულების შემდეგ, ლიეტუველ და ჰოლანდიელ ექსპერტებს მივწერეთ თხოვნა, 2.1.1 აქტივობის ფარგლებში ჩამოაყალიბონ ეროვნული კომპეტენტური ორგანოს ფუნქციები სამი შესაძლო უწყების დაქვემდებარებაში ოპერირების შემთხვევაში. გთხოვთ, იხილოთ იმეილი ქვემოთ:

Dear experts,

Would you kindly suggest, as Dr. Gamkrelidze asked you all, tentative functionalities of the future blood safety system monitoring organization or unit, given that the three major players will be: a. Ministry of Health,
b. Regulatory Agency, c. NCDC.

What are potential challenges if the future NCA operates under each of these three bodies?

What should we pay special attention to?

როგორც მოსალოდნელი იყო, მათ გვთხოვეს ინფორმაციის მიწოდება აღნიშნული სამი უწყების - სამინისტრო, სააგენტო და NCDC პასუხისმგებლობების შესახებ.

გთხოვთ, არაუგვიანეს ოთხშაბათს დღის პირველი ნახევრისა, უზრუნველყოთ აღნიშნული ინფორმაციის ექსპერტებისთვის მიწოდება. მათთან შევთანხმდით, რომ მეორე ონლაინ ჩართვა პარასკევს, 17 ივლისს გვექნება საქართველოში NCA-ს ფუნქციების განსახილველად.

წინასწარ გიხდით მადლობას,

პატივისცემით,

ქეთი

Ketevan Khizanishvili

RTA Assistant

Twinning Project Strengthening Blood Safety System in Georgia

Mob: (+995) 599 155 002

---------- Forwarded message ---------
From: Smid, Martin <[email-masked]>
Date: Mon, Jul 13, 2020 at 4:20 PM
Subject: RE: Activity 2.1.1 - follow-up
To: Keti Khizanishvili <[email-masked]>, [email-masked] <[email-masked]>, Ardenne-Stachiw, Olenka van <[email-masked]>, Laimutė Stonienė <[email-masked]>, Wim de Kort <[email-masked]>
Cc: Amiran Gamkrelidze <[email-masked]>, turkia babilina <[email-masked]>, Vladimer Getia <[email-masked]>, Algirdas Gri <[email-masked]>, Kakhaber Dvalidze <[email-masked]>

Dear Keti,

It was a pleasure to be part of the round table conference with the colleagues in Georgia and Lithuania.

As I understand your e-mail this week the continuation of the work with discussions in Georgia to prepare the final decisions
with a videoconference on Friday seems a  excellent approach. Will check the presence of the other Dutch experts for Friday as well.

As to you question it will be certainly helpful to receive the information about the responsibilities of the three institutes
regarding the responsibilities.

Kind regards, Martin

Dr. W. Martin Smid

Managing Director Sanquin Consulting Services

Director Academic Institute IDTM

Chair ISBT WP Global Blood Safety

Tel: +31-20-512 3680 |Mob: +31-653 682 792

Email:
[email-masked]

Plesmanlaan 125

1066 CX Amsterdam

The Netherlands

www.sanquin.org

www.idtm-mtm.org

www.groningenbiomed.com/mtm

Van: Keti Khizanishvili [mailto:[email-masked]]

Verzonden: maandag 13 juli 2020 14:01

Aan: Smid, Martin <[email-masked]>; [email-masked]; Ardenne-Stachiw, Olenka van <[email-masked]>; Laimutė Stonienė <[email-masked]>; Wim de Kort <[email-masked]>

CC: Amiran Gamkrelidze <[email-masked]>; turkia babilina <[email-masked]>; Vladimer Getia <[email-masked]>; Algirdas Gri <[email-masked]>; Kakhaber Dvalidze <[email-masked]>

Onderwerp: Activity 2.1.1 - follow-up

Dear experts,

First of all, I would like to thank you all for participating in today's teleconference.

We would like to offer you to organize the second day of activity 2.1.1 at the end of this week, on July 17th. During the next three days the Georgian working group members will have internal discussions regarding the
draft legislation on blood safety, as well as the organizational structure of future institution.

Would you kindly suggest, as Dr. Gamkrelidze asked you all, tentative functionalities of the future blood safety system monitoring organization or unit, given that the three major players will be: a. Ministry of Health,
b. Regulatory Agency, c. NCDC.

What are potential challenges if the future NCA operates under each of these three bodies?

What should we pay special attention to?

We do not want to overstretch ourselves  but the more detailed your suggestions are, the more immensely grateful we will be. We understand that the burden of making decisions is entirely upon the Georgian side, but your
expert advices will be invaluable in helping us make that decision.

If necessary, we can provide you with very thorough information and relevant current functions about all three institutions.

Thank you in advance,

With Regards,

Keti

Ketevan Khizanishvili

RTA Assistant

Twinning Project Strengthening Blood Safety System in Georgia

Mob: (+995) 599 155 00

Disclaimer: http://www.sanquin.nl/e-maildisclaimer